GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kazia Therapeutics Ltd (NAS:KZIA) » Definitions » Revenue

KZIA (Kazia Therapeutics) Revenue : $1.53 Mil (TTM As of Jun. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Kazia Therapeutics Revenue?

Kazia Therapeutics's revenue for the six months ended in Jun. 2024 was $1.53 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $1.53 Mil. Kazia Therapeutics's Revenue per Share for the six months ended in Jun. 2024 was $0.53. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.53.

Warning Sign:

Kazia Therapeutics Ltd revenue per share has been in decline over the past 3 years.

During the past 3 years, the average Revenue per Share Growth Rate was -61.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Kazia Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 277.00% per year. The lowest was -61.10% per year. And the median was -16.40% per year.


Kazia Therapeutics Revenue Historical Data

The historical data trend for Kazia Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kazia Therapeutics Revenue Chart

Kazia Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 11.61 - - 1.53

Kazia Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 1.53

Competitive Comparison of Kazia Therapeutics's Revenue

For the Biotechnology subindustry, Kazia Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kazia Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Revenue falls into.



Kazia Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kazia Therapeutics  (NAS:KZIA) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Kazia Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Kazia Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kazia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
Executives
Josiah T Austin director, 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204
El Coronado Holdings, Llc 10 percent owner 4673 CHRISTOPHER PLACE, DALLAS TX 75204